The Combination of the Proteasome Inhibitor Bortezomib and the BCL-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-05-0308
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Sensitizing Human Multiple Myeloma Cells to the Proteasome Inhibitor Bortezomib by Novel Curcumin Analogs

International Journal of Molecular Medicine
MedicineGenetics
2011English

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib

PLoS ONE
Multidisciplinary
2013English

Effects of the Proteasome Inhibitor Bortezomib in Combination With Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-Analysis

Turkish Journal of Haematology
Hematology
2019English

Proteasome Inhibitor Bortezomib Modulates TLR4-induced Dendritic Cell Activation

Blood
BiochemistryImmunologyCell BiologyHematology
2006English

Loss in McL-1 Function Sensitizes Non-Hodgkin’s Lymphoma Cell Lines to the BCL-2-selective Inhibitor Venetoclax (ABT-199)

Blood Cancer Journal
OncologyHematology
2015English

EZH2 Inhibition Re-Sensitizes Multidrug Resistant B-Cell Lymphomas to Etoposide Mediated Apoptosis

Oncoscience
Cancer ResearchOncology
2016English

From Bortezomib to Other Inhibitors of the Proteasome and Beyond

Current Pharmaceutical Design
Drug DiscoveryPharmacology
2013English

Calcineurin and M-Tor Inhibitor-Free Post-Transplant Cyclophosphamide (PTC) and Bortezomib (B) Combination for the Prevention of Graft-Versus-Host Disease (GvHD): Phase I-Ii Study

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

The Proteasome Inhibitor Bortezomib Attenuates Renal Fibrosis in Mice via the Suppression of TGF-β1

Scientific Reports
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy